The Next Generation of Vaccines and Immunotherapies

Site Map | Copyright | Home

 

Virionics Mission

At Virionics, our mission is to develop and commercialize virus-like particles (VLPs), a groundbreaking, new medical technology that harnesses the power of the immune system to treat and prevent a wide variety of diseases. Learn more >>

 

News and Updates

2006.04.04

Virionics Corporation Signs MediGene AG License Agreement; Acquires Clinical Phase II CVLP Program Assets in Exchange for Equity
Learn more >>

What is a Virus-Like Particle (VLP)?

VLPs are genetically-engineered, self-assembled protein spheres made from recombinant viral proteins. These three dimensional, multi-antigen particles have already proven to be safer and more effective as preventative vaccines and immunotherapies when compared to recombinant protein, DNA, or viral-vectored vaccines.
Learn more >>

VLP Product Development

PapViRx, our lead product, is being prepared to enter an international Phase II/III clinical trial in 2008.
Learn more >>

HepCVax and HepCiRx for the prevention and treatment of hepatitis C virus (HCV) is being prepared for pre-clinical and Phase I clinical trials
Learn more >>

Phase I-II studies of CIgImmune for liver transplant patients and HepCiRx are planned for 2008.

Virionics plans to collaborate with NGOs to advance novel, dual-action HIV vaccine for prevention of HIV infection and AIDS.
Learn more >>